Ganglioneuroblastoma is an intermediate form of neuroblastic tumors arising from the peripheral sympathetic nervous system, occupying a maturation spectrum between neuroblastoma and ganglioneuroma. Histologically, it contains both mature ganglion cells and immature neuroblasts. Although more common in childhood and adolescence, it can also occur in young adults. Originating from the adrenal medulla, this tumor has a better prognosis than neuroblastoma but may follow a more aggressive course than ganglioneuroma. On imaging, its heterogeneous composition produces both solid and cystic areas, calcifications, and a variable enhancement pattern. It may secrete catecholamines but at lower levels than neuroblastoma; urine VMA and HVA may be mildly elevated. Surgical resection is the mainstay of treatment, and prognosis depends on histological subtype and presence of nodular component.
Age Range
0-20
Peak Age
5
Gender
Equal
Prevalence
Rare
Ganglioneuroblastoma develops from neural crest-derived cells and arises in sympathetic nervous system ganglia or the adrenal medulla. The tumor forms through partial maturation of neuroblastoma; immature neuroblasts coexist with mature ganglion cells and Schwann cell stroma. This dual-component structure underlies the heterogeneous signal and enhancement pattern on imaging — mature stromal areas show low enhancement while immature neuroblastic components enhance more intensely. The catecholamine synthesis capacity of neuroblastic cells manifests as uptake on functional imaging (MIBG scintigraphy); however, mature ganglion cells do not take up MIBG, which explains the heterogeneous uptake pattern. Calcifications develop in areas of dystrophic calcification or necrosis and appear as punctate or coarse calcification on CT. The tumor's myelin sheath components produce high signal on T2-weighted MRI, while fibrous stromal components may show low T2 signal — this mixed signal pattern reflects the tumor's heterogeneous histological composition.
The coexistence of areas with active uptake (immature neuroblastic) and areas without uptake (mature ganglioneuromatous) within the tumor on MIBG scintigraphy is a characteristic signature finding for ganglioneuroblastoma. This pattern positions the tumor between pure neuroblastoma (diffuse intense uptake) and ganglioneuroma (no uptake).
On non-contrast CT, a heterogeneous density mass is seen in the adrenal lodge or retroperitoneal space. Coarse and punctate calcifications are frequently observed within the tumor (50-80% of cases). Solid areas show soft tissue density (30-50 HU) while cystic/necrotic areas approximate fluid density (10-20 HU). Calcifications have an irregular distribution but may show a more organized pattern compared to neuroblastoma. Tumor size is variable, generally ranging from 3-10 cm.
Report Sentence
A heterogeneous density mass containing coarse and punctate calcifications is seen in the adrenal lodge/retroperitoneal space; neuroblastic tumor spectrum (ganglioneuroblastoma) should be considered as the leading diagnosis.
Heterogeneous enhancement is observed on contrast-enhanced CT in the arterial phase. Immature neuroblastic areas show more intense enhancement while mature ganglioneuromatous areas enhance less. Cystic and necrotic areas do not enhance. The enhancement pattern displays an intermediate appearance between neuroblastoma and ganglioneuroma — neither as intense and diffuse as neuroblastoma nor as minimal as ganglioneuroma. Peritumoral vascular structures may be prominent but less vascular invasion is expected compared to neuroblastoma.
Report Sentence
The mass demonstrates heterogeneous enhancement in the arterial phase, and the coexistence of intensely enhancing and non-enhancing areas suggests an intermediate differentiation level within the neuroblastic tumor spectrum.
On T2-weighted MRI, the tumor shows predominantly hyperintense signal with significant heterogeneity. Mature ganglioneuromatous areas demonstrate very high T2 signal due to myxoid stroma, while fibrous stromal areas show low T2 signal. Neuroblastic components have intermediate-to-high T2 signal. Cystic and necrotic areas show very high T2 signal, while calcified areas demonstrate low signal on all sequences. This heterogeneous signal pattern reflects the tumor's components at different maturation levels.
Report Sentence
The mass demonstrates heterogeneous, predominantly hyperintense signal on T2-weighted images, consistent with a mixture of myxoid, fibrous, and neuroblastic components; ganglioneuroblastoma should be primarily considered in the differential diagnosis.
On T1-weighted images, the tumor generally shows iso- to hypointense signal relative to muscle. Hemorrhagic areas may appear as T1 hyperintense foci — particularly prominent in subacute hemorrhage foci (methemoglobin content). Calcified areas show low signal on T1. Cystic areas show low T1 signal, while proteinaceous cystic areas may demonstrate mild T1 hyperintensity.
Report Sentence
The mass demonstrates iso- to hypointense signal on T1-weighted images, with focal T1 hyperintense areas consistent with subacute hemorrhagic component.
On diffusion-weighted imaging, the tumor shows heterogeneous diffusion restriction. Immature neuroblastic components demonstrate marked diffusion restriction (low ADC values, typically 0.6-0.9 × 10⁻³ mm²/s) due to high cellular density, while mature ganglioneuromatous areas show less restriction (ADC 1.2-1.8 × 10⁻³ mm²/s). This ADC value difference reflects the maturation level within the tumor and may help estimate the neuroblastic component proportion.
Report Sentence
The mass demonstrates heterogeneous diffusion restriction on diffusion-weighted images, with areas of marked restriction consistent with immature neuroblastic component.
On I-123 or I-131 MIBG scintigraphy, the tumor demonstrates heterogeneous uptake. Immature neuroblastic areas actively take up MIBG while mature ganglioneuromatous areas show no or minimal uptake. This heterogeneous uptake pattern helps distinguish ganglioneuroblastoma from both neuroblastoma (diffuse intense uptake) and ganglioneuroma (no uptake). SPECT/CT provides anatomical correlation for precise localization of uptake areas.
Report Sentence
Heterogeneous uptake is observed in the mass on MIBG scintigraphy, with areas of active uptake consistent with immature neuroblastic component and non-uptake areas consistent with mature ganglioneuromatous component.
On post-gadolinium T1-weighted images, the tumor demonstrates heterogeneous enhancement. Immature neuroblastic areas show prominent enhancement while mature Schwann cell stroma enhances minimally. Cystic and necrotic areas do not enhance, but thin rim enhancement may be seen around necrotic areas. In the nodular subtype, enhancing nodular areas represent immature neuroblastic components and have prognostic significance.
Report Sentence
The mass demonstrates heterogeneous enhancement on post-gadolinium T1-weighted images, with enhancing nodular areas consistent with immature neuroblastic components.
Criteria
Neuroblastic cell nests dispersed within mature ganglion cells and Schwann cell stroma. Schwannian stroma dominant (more than 50%). Favorable histology according to INPC.
Distinct Features
More homogeneous structure on imaging, fewer calcifications, predominantly T2 hyperintense pattern similar to ganglioneuroma on MRI. Low or minimal MIBG uptake. Excellent prognosis — surgery is curative.
Criteria
One or more macroscopic neuroblastic nodules within a ganglioneuroma or intermixed GNB background. Nodules show stroma-poor neuroblastoma characteristics. May have unfavorable histology according to INPC.
Distinct Features
Most prominent heterogeneity on imaging — intensely enhancing nodular areas within a smooth-bordered mass. More intense calcification in nodular areas on CT. Nodular areas show marked diffusion restriction on MRI. MIBG uptake intense in nodules. Prognosis depends on N-MYC amplification.
Criteria
Multiple neuroblastic nodules within a ganglioneuroma or intermixed GNB background, with each nodule potentially at different differentiation grades. Prominent inter-nodular maturation difference.
Distinct Features
Multiple nodular areas with different enhancement patterns on imaging — each nodule may show different DWI, ADC, and enhancement characteristics. Each nodule may have different uptake intensity on MIBG. Prognosis determined by the most aggressive nodule.
Distinguishing Feature
Neuroblastoma shows diffuse intense MIBG uptake; ganglioneuroblastoma shows heterogeneous/focal uptake. Neuroblastoma occurs at younger age (<5 years), more aggressive course, higher catecholamine levels, and tendency for vascular invasion.
Distinguishing Feature
Ganglioneuroma is typically a homogeneous T2 hyperintense, minimally enhancing, well-defined mass; no MIBG uptake. Ganglioneuroblastoma shows heterogeneous signal and enhancement. Calcification is rarer in ganglioneuroma. Ganglioneuroma shows no diffusion restriction on DWI.
Distinguishing Feature
Pheochromocytoma shows very bright 'light bulb' T2 signal, intense enhancement, and elevated catecholamine levels. Calcification is rare, cystic degeneration common. MIBG uptake is diffusely intense. Pheochromocytoma is more common in adults.
Distinguishing Feature
Adrenocortical carcinoma is generally large (>6 cm), irregularly bordered, heterogeneous mass with necrosis and hemorrhage. Calcification less common than neuroblastic tumors. Different hormonal syndromes (Cushing, virilization). No MIBG uptake. More common in adults.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
3-monthGanglioneuroblastoma has intermediate aggressiveness in the neuroblastic tumor spectrum. Surgical resection is the primary treatment. Preoperative biopsy is important for histological subtype determination and risk stratification — the nodular subtype may follow a more aggressive course and require additional chemotherapy. Urine catecholamine levels are used in diagnosis and follow-up. MIBG scintigraphy is valuable for staging and recurrence monitoring. In the intermixed subtype, prognosis after complete resection is excellent (>90% 5-year survival). In the nodular subtype, prognosis depends on neuroblastic component characteristics. Postoperative follow-up is performed with imaging and catecholamine levels at 3-6 month intervals.
Ganglioneuroblastoma has a better prognosis than neuroblastoma. Surgical resection is the primary treatment. Nodular subtype has worse prognosis (closer to neuroblastoma). MIBG scintigraphy is used for staging.